{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T15:01:41Z","timestamp":1763046101313,"version":"3.45.0"},"reference-count":0,"publisher":"American Psychological Association (APA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental and Clinical Psychopharmacology"],"DOI":"10.1037\/pha0000686","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T17:13:17Z","timestamp":1699031597000},"page":"263-269","source":"Crossref","is-referenced-by-count":0,"title":["Mental health facilities with ketamine infusion therapy in the United States in 2020: Co-location of dual diagnosis mental health and substance use disorder treatment."],"prefix":"10.1037","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3269-5324","authenticated-orcid":false,"given":"Orrin D.","family":"Ware","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"15","published-online":{"date-parts":[[2024,6]]},"container-title":["Experimental and Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/psycnet.apa.org\/journals\/pha\/32\/3\/263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:57:18Z","timestamp":1763045838000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.apa.org\/doi\/10.1037\/pha0000686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["2024-22191-001","37917509"],"URL":"https:\/\/doi.org\/10.1037\/pha0000686","relation":{},"ISSN":["1936-2293","1064-1297"],"issn-type":[{"type":"electronic","value":"1936-2293"},{"type":"print","value":"1064-1297"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}